{"document_type": "article", "byline": [], "news_desk": "Letters", "slideshow_credits": null, "abstract": null, "multimedia": [], "headline": {"kicker": "Letter", "content_kicker": "Letter", "main": "The Generic Drug Market"}, "print_page": null, "keywords": [{"value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "1", "name": "subject"}, {"value": "Generic Brands and Products", "is_major": "N", "rank": "2", "name": "subject"}], "snippet": "The Healthcare Supply Chain Association says the backlog of new generic drug applications at the F.D.A. is compounding the problem of price increases.", "source": "The New York Times", "lead_paragraph": "The Healthcare Supply Chain Association says the backlog of new generic drug applications at the F.D.A. is compounding the problem of price increases.", "word_count": "255", "pub_date": "2016-05-19T00:00:00Z", "subsection_name": null, "blog": [], "type_of_material": "Letter", "section_name": "Opinion", "web_url": "http://www.nytimes.com/2016/05/19/opinion/the-generic-drug-market.html", "_id": "573c916038f0d86c87c2cefb"}